English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine MedTech
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025
Feb 14, 2025 20:00 HKT
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10
Jan 24, 2025 23:00 HKT
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 09, 2025 08:00 HKT
World's first high-standard negative-pressure isolation ward built with MiC technology completes historical mission
Dec 30, 2024 20:04 HKT
全球首个组装合成可快速建造高规格负压隔离病房完成历史任务
Dec 30, 2024 18:10 HKT
全球首個組裝合成可快速建造高規格負壓隔離病房完成歷史任務
Dec 30, 2024 17:43 HKT
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 09, 2024 13:00 HKT
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
Dec 02, 2024 21:30 HKT
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利
Dec 02, 2024 20:49 HKT
康哲药业获得治疗痛风及高尿酸血症的1类新药独家商业化权利
Dec 02, 2024 20:37 HKT
愛康醫療三度榮膺北京市科技一等獎 推動髖關節發育不良診療技術革新
Nov 20, 2024 19:35 HKT
爱康医疗三度荣膺北京市科技一等奖 推动髋关节发育不良诊疗技术革新
Nov 20, 2024 19:12 HKT
康哲药业入选2024年度“中国医药上市公司ESG竞争力”系列榜单
Oct 21, 2024 19:15 HKT
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area
Oct 21, 2024 10:00 HKT
康哲药业:芦可替尼乳膏(白癜风)大湾区首批处方落地
Oct 18, 2024 14:44 HKT
康哲药业:磷酸芦可替尼乳膏(白癜风)中国上市许可申请已获受理
Sep 24, 2024 21:20 HKT
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
Sep 24, 2024 21:00 HKT
Taiwan Excellence Pavilion concludes Medical Fair Asia 2024 with Showcase of Cutting-Edge MedTech Innovations
Sep 13, 2024 17:50 HKT
Taiwan Excellence Unveils Pioneering Medtech Innovation at Medical Fair Asia 2024
Sep 05, 2024 23:00 HKT
Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024
Aug 23, 2024 08:00 HKT
Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: